Compare SDHC & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDHC | ONCY |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.3M | 94.0M |
| IPO Year | 2023 | 2002 |
| Metric | SDHC | ONCY |
|---|---|---|
| Price | $13.73 | $1.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $14.60 | $7.33 |
| AVG Volume (30 Days) | 202.5K | ★ 831.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $971,116,000.00 | N/A |
| Revenue This Year | $4.21 | N/A |
| Revenue Next Year | $11.07 | $2,505.00 |
| P/E Ratio | $11.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.13 | $0.33 |
| 52 Week High | $23.50 | $1.51 |
| Indicator | SDHC | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 56.46 |
| Support Level | $11.18 | $0.94 |
| Resistance Level | $14.49 | $1.13 |
| Average True Range (ATR) | 0.77 | 0.08 |
| MACD | 0.32 | 0.02 |
| Stochastic Oscillator | 48.33 | 79.69 |
Smith Douglas Homes Corpis a builder of single-family homes in communities in certain markets in the southeastern and southern United States. The Company's homes and communities are targeted to first-time and empty-nest homebuyers. The Company currently operates in metropolitan Atlanta, Birmingham, Chattanooga, Central Georgia, Charlotte, Dallas-Fort Worth, Greenville, Alabama Gulf Coast, Huntsville, Nashville, Raleigh and Houston. Its operations are currently organized into ten geographical divisions which comprise two reportable segments. Its Southeast segment consists of its Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of its Alabama, Dallas-Fort Worth, Houston, Nashville, and Alabama Gulf Coast divisions.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.